TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05704465

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reiki Therapy
Description: Reiki therapy involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. In this technique, energy is guided by therapist's hands placed near patient's body to activate the ability of the body to heal and restore its balance. 1st session for explanation of aim and objectives of program. 2nd one focused on knowledge about negative emotional state. 3rd one discussed Reiki technique and its concept, mode of action, and process. The 4th through 7th sessions were practical. During these sessions, a Reiki practitioner moves his/her hands close to the patient's body in a set of positions. Each hand position focuses on a different part of the body. The hands are held in position for 3 to 10 min., depending on patient's needs. By the end of the session, the patient and therapist reflect on their experience and the emotions with the technique. The eighth session was a recapitulation of the program and ended with evaluation or post-testing.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Qi-gong Therapy
Description: Qi-gong involved 3 theoretical sessions, 4 practical sessions, and one final one for recapitulation and evaluation. It involves coordination of breathing and physical movement with mental energy to promote cognitive performance. Both 1st and 2nd sessions were similar to Reiki technique group. The 3rd one addressed the concept of Qi-gong therapy. The 4th through 7th sessions involved patients' doing simple movements and breathing techniques. The practitioner is at about a one-foot distance from the patient's body, to guide and manipulate movements. Breathing patterns are like yoga, with Qigong movements in a mindful link to inspiration and expiration, with incorporation of deep diaphragmatic breathing. The 8th session was similarly for program recapitulation and post-testing.
Study: NCT06225050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CliniMACS Prodigy® LP-TCRα/β-19-45RA (Trial Version)
Description: PBSC grafts from haploidentical donors depleted of TCRaβ+ cells and CD45RA+ cells using CliniMACS Prodigy® will be infused into patients intravenously (IV)
Study: NCT05599516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIBP-Rec-Vaccine
Description: Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIBP-Rec-Vaccine
Description: Intramuscular injection of LIBP-Rec-Vaccine in the deltoid muscle of the upper arm
Study: NCT06158750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: p64/p48 MW HPC Flow Modulation Device
Description: Endovascular intervention with p64/p48 MW HPC Flow Modulation Device was performed in patients diagnosed with intracranial aneurysms
Study: NCT06116279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insertion of electrode during planned neurosurgery for epilepsy
Description: A novel, 300 micrometer, ultraflexible, low-impedance electrode proposes to cause minimal parenchymal (brain tissue) damage, and provide multiple contacts at multiple depths to allow unit-level recordings for a period of 15 minutes.
Study: NCT05885503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RC-28E
Description: Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept
Description: Ophthalmic solution for intravitreal injection administered as a 2.0mg/50 μL per dose.
Study: NCT06362915

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: * Group (A) lidocaine : will receive blind local infiltration in femoral region on the operation side by an experienced anesthesiologist using 20 ml lidocaine 1%.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: • Group (B),bupivacaine: will receive ultrasound-guided ilioinguinal/iliohypogastric nerve block using 20 ml Bupivacaine 0.25% by an experienced anesthesiologist
Study: NCT05103982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping with Infertility Program
Description: 6 10-minute videos with assigned homework
Study: NCT05772546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avatrombopag
Description: Thrombopoietin receptor agonist, tablet taken orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo
Description: Lactose monohydrate, tablet taken orally.
Study: NCT05534581

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using the Arctic Front Cryoballoon (Medtronic)
Description: Patients randomized to the Arctic Front cryoballoon group will undergo PVI using the Arctic Front Cryoballoon (Medtronic). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PVI using FARAPULSE Pulsed Field Ablation (Boston Scientific)
Description: Patients randomized to the Pulsed Field Ablation group will undergo PVI using the FARAPULSE PFA system (Boston Scientific). At the end of the procedure, an implantable cardiac monitor will be implanted for the purpose of continuous arrhythmia monitoring.
Study: NCT05599516

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBP-Rec-Vaccine
Description: Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BIBP-Rec-Vaccine
Description: Intramuscular injection of BIBP-Rec-Vaccine in the deltoid muscle of the upper arm
Study: NCT05184725

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaMD CARINAE
Description: SaMD CARINAE delivers the following digital therapeutic intervention to the patients: 1) Personalised patient-centred health education program to improve patient's disease and recovery self-management skills. 2) AI-based behaviour change program to promote healthier lifestyle habits. 3) Personalised mental well-being coaching program to improve patient's ability to cope with emotional disturbances such as stress and anxiety. 4) A collaborative digital support platform to enable information exchange between patients, caregivers, and healthcare professionals.
Study: NCT05777902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod Oral Capsule
Description: We propose to integrate measurements obtained using multiple tools. Patients will undergo MRI and hdEEG procedures, and blood samples will be obtained for the immunological and biochemical studies on the same day. The study of the immune system's status will include an extensive immunophenotypic analysis, a functional characterization following ex vivo stimulation of innate immune cells, and the measurement of soluble products in the serum, such as cytokines. Cellular traits of interest include the absolute numbers and relative proportions of specific cell subsets, transcriptional states, secretory functions, proliferative capacity or cytolytic potential. Specifically, the following antibody combination will constitute the core of the immunophenotypic analysis: HLADR CD11c, CD38, CD14, CD123, lineage (CD3, CD56, CD19).
Study: NCT05800132

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MammoScreen
Description: Diagnostic reading aid for breast cancer screening
Study: NCT05813873

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triflow
Description: Triflow

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Exercise
Study: NCT05720806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weight Bearing as tolerated (WBAT) immediately following surgery.
Description: Subject will be provided standard of care physical therapy following surgical intervention, except will be able to self-select weight bearing based on pain and confidence.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flat foot weight bearing (FFWB) immediately following surgery
Description: Subject will be provided standard of care physcial therapy following surgical intervention except
Study: NCT05600231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE COOL MINT Antiseptic Mouthwash
Description: Participants will use LISTERINE COOL MINT Antiseptic Mouthwash for 30 second after brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE COOL MINT ZERO Alcohol Mouthwash
Description: Participants will use LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 second after brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LISTERINE COOL MINT ZERO Alcohol Mouthwash
Description: Participants will use LISTERINE COOL MINT ZERO Alcohol Mouthwash for 30 second after brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Unflavored Waxed Dental Floss
Description: Participants after brushing for 1 timed minute, will rinse mouth with water and Floss once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reach Unflavored Waxed Dental Floss
Description: Participants after brushing for 1 timed minute, will rinse mouth with water and Floss once a day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study: NCT05599516

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Intramuscular injection of placebo in the deltoid muscle of the upper arm
Study: NCT05600231

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Colgate Cavity Protection Toothpaste
Description: Participants will use Colgate Cavity Protection Toothpaste for brushing teeth twice daily.
Study: NCT05017350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation
Description: Under the ultrasound guidance, the electrode is inserted into the bleeding focus of the liver and the bleeding focus is ablated.
Study: NCT04661683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combustible Hookah Smoke
Description: Exposure to combustible hookah smoke for a duration of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Hookah Aerosol
Description: Exposure to electronic hookah aerosol for a duration of 60 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clean Room Air
Description: Exposure to room air for a duration of 60 minutes.
Study: NCT06134544

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Isomaltooligosaccharides (IMO)
Description: Patients will still receive standard treatment, including medicine and other invasive treatment.
Study: NCT05164159

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol group
Description: During induction, the propofol group starts the effect site concentration at 4.0 ng/ml with TCI and adjusts it to around 3.0 \~ 4.0 ng/ml after intubation to maintain an appropriate EEG-based depth of anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remimazolam group
Description: In the remimazolam group, start remimazolam at 6 mg/kg/hr and adjust it to 1 mg/kg/hr after loss of consciousness to maintain an appropriate EEG-based depth of anesthesia.
Study: NCT06104410

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Standard fractioned dose
Description: Total dose of 6 Gy in 2 or 4 single fractions of 1.5 Gy applied twice weekly.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Experimental single dose
Description: Total dose of 0.5 Gy, 1Gy, 1.5 or 2Gy in 1 single fraction.
Study: NCT05538156

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group
Description: Vitrectomy and gas tamponade without internal limiting membrane peeling

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intervention group
Description: Vitrectomy, internal limiting membrane peeling and gas tamponade
Study: NCT04285476

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Signature of microRNA for patients with bethesda classification 3, 4 or 5
Description: If the cytology results are Bethesda 3, 4 or 5, then a miRNA analysis will be performed.
Study: NCT05855499

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPtcube, CPTpatch
Description: This study investigates the effectiveness of a system for reproducible application of cold plasma on larger areas and observes the effect of a 4-week additional plasma treatment on wound healing of large chronic wounds.
Study: NCT02214836

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verasonics Data Acquisition System (VDAS)
Description: Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
Study: NCT05418335

Intervention type: OTHER
Intervention: Clinical examination, functional status evaluation
Description: Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index

Intervention type: OTHER
Intervention: Clinical examination, functional status evaluation
Description: Barthel Index, Oral Health Impact Profile 14, Beck Depression Inventory, Stroke Impact Scale 3, Plaque Index, Calculus Index, Periodontal Disease Index, Simplified Oral Hygiene Index assesment, DMFT Index
Study: NCT05225285

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Coronavac/Butantan vaccine
Description: Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Coronavac/Butantan vaccine
Description: Inactivated Coronavac/Butantan vaccine in 2 doses of 0.5 ml, 4 weeks apart

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BNT162b2 (Pfizer)
Description: BNT162b2 (Pfizer) vaccine in 2 doses of 0.1 ml or 0.30 ml (according to age group), 4 weeks apart
Study: NCT05530928

Intervention type: OTHER
Group type: OTHER
Intervention: Reproductive life plan counseling
Description: The intervention group will receive in addition to the standard contraceptive counseling, a reproductive life plan counseling: midwives will discuss the different options with the woman depending if she wants or not more children, and she will give her general information about preconception health.
Study: NCT06577142

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Burn 2 Learn
Description: The 'Burn 2 Learn' group encompassed the following components and implementations. A brief introductory seminar will be conducted with the principle, school event coordinator, school sports teacher and students from grade 8 to 10. The aim of this seminar is to provide a better understanding of the rationale and presenting evidence of the beneficial effects of high intensity interval training on overall wellbeing of students. The sessions will be conducted thrice a week for 10 to 15 minutes by the research team members for a period of 10 weeks. The sessions will consist of high intensity interval training activities such as lunges, jumping jacks, boxing, dancing and sports activities. The intervals ranging between 8-16, 30 second work out followed by 30 seconds rest, maintaining a 1:1 work rest ratio.~51 participants will be in the experimental group A giving them Burn 2 Learn exercise protocol along with the normal sports training plan for ten weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: 51 participants will be in control group B and will perform their routine school physical activities, sports games or any exercise routines.
Study: NCT06443957

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal normal saline
Description: The patient was given 1ml of normal saline intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin-20U
Description: The patient was given 1ml of 20U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal insulin-40U
Description: The patient was given 1ml of 40U insulin intranasally at 19:00 on the first day of surgery, 50 minutes before anesthesia on the day of surgery, and 19:00 on the day of surgery.
Study: NCT05487937

Intervention type: OTHER
Intervention: Use of Toleriane Ultra to relieve face allergic skin
Description: The product developed to restore the natural skin barrier and rebalance skin immune system is a white cream and is applied on the face by a slight massage under normal conditions of use twice daily for 28 days.
Study: NCT06346470

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based breast self examination education
Description: Students in this group will receive web-based breast self-examination education for 6 hours .
Study: NCT06134284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib combined with rituximab
Description: This is a single-arm trial. Patients with relapsed/refractory marginal zone lymphoma will be treated with the OR regimen. The treatment plan is as follows: Orelabrutinib 150mg oral administration once a day, Day 1-21; Rituximab 375mg/m² intravenous infusion, Day 1. Each cycle is 21 days. PET-CT evaluation will be conducted after 4 cycles. If a partial response (PR) or better is achieved, the patient will receive further treatment with the OR regimen for an additional 4 cycles before transitioning to single-agent maintenance therapy with either rituximab or obinutuzumab. If a PR or better is not achieved after 4 cycles, the patient will discontinue from the trial.
Study: NCT05871047

Intervention type: DEVICE
Intervention: tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application
Description: Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.

Intervention type: DEVICE
Intervention: tragus to wall distance (TWD), craniovertebral angle (CVA) by smart phone application
Description: Applying photogrammetric method for CVA by smart phone application and measure nerd neck objectively from both sitting and standing positions. Also, tragus to wall distance method was used to detect degree of nerd neck from the standing position.
Study: NCT05190770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Triamcinolone acetonide is a derivative of prednisolone with high glucocorticoid activity and low mineralocorticoid activity. It is applied topically.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oleogel-S10
Description: Oleogel-S10 consists of birch bark extract (TE): 10 mg/100 mg; Sunflower oil, refined: 90 mg/100 mg. It is applied topically.
Study: NCT06271785

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: HR-EEG recording
Description: All participants will have a HR-EEG recordings. It will be made at rest. Nap-like sleep is encouraged, but no sedatives will be given. Recording time will not exceed two hours.
Study: NCT04548193

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive live phone call

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Receive live phone call

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Dietary Intervention
Description: Receive IVR phone messages

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Dietary Intervention
Description: Receive IVR phone messages

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Receive educational materials

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05921929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoroethylnormemantine (FENM)
Description: Single ascending oral dose administration according to the following scheme: 20, 40, 80, 120-160, 200-240, 260-320mg/kg (six dose levels). The three upper dose levels to be administered (120-160, 200-240, 260-320mg/kg) will be precisely determined with the data collected at the end of the first three dose levels administered.
Study: NCT05558241

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution micro-ultrasound
Description: In a single biopsy session, first, a microUS-guided biopsy of regions of interest (ROIs) will be performed. The MRI fusion software will then be turned on, the clinician unblinded to the MRI results, and biopsy cores from within the boundaries of the MRI-fused lesion will be sampled from ROIs. Up to two ROIs identified on microUS or MRI will be targeted with up to 3 cores per ROI. If the MRI ROIs overlap with the microUS ROIs after unblinding, then the cores taken during the microUS-guided biopsy will be counted as both microUS and MRI-guided. Finally, a standard 12-core systematic biopsy will be performed.
Study: NCT06139471

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-Enhanced Gagne's Instructional Model
Description: Virtual Reality-Enhanced Gagne's Instructional Model
Study: NCT04856306

Intervention type: OTHER
Intervention: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure
Description: See previous descriptions

Intervention type: OTHER
Intervention: Groups 1 and 2 myomectomy and uterine artery embolization, respectively, are surgical/procedure
Description: See previous descriptions

Intervention type: DRUG
Intervention: Elagolix Oral Product
Description: See group 3 description